>> celgene. ? >> celgene is okay. i like the quarter. it's okay. i mean, okay. what have we got here? let's go to joe in jersey. joe. >> caller: hello, cramer. i was rooting for your eagles last night. tough loss. >> okay. go ahead. >> caller: my stock is hewlett-packard inc., hpq. >> i like hpq. i think it's good. doesn't make up for last night, but it's good stock. you know, on the fourth and one, i would have kicked and missed the field goal. mo in new jersey, mow. >> caller: hey, gyp. how are you? >> i'm okay. i'm trying to recover from the previous couple of calls. what's going on? >> caller: i'm calling about oncology which got a lot of hype back in august because of the fda. it had a strong dip after its less than spectacular lab results. i just want to know is there anything i should be waiting for. >> it's speculativspeculative. i think celgene is fine. i think merck with that yield is good. that's the way i would go. brian in california, brian. >> caller: booyah, jim. greetings from gray eagle, california. >> oh, man, did he say eagles? >> caller: gray

some big names in biotech, colleague biogen, amgen and celgene.ver 3% over wednesday's earnings announcement. biogen, the options market implying a 3% move in either direction. for biogen, a 6% move up or down. together, all three, biotech giants have an implied market move of over $10 billion. this as biotech stocks have fallen 10% over the past month, due in part to the political rhetoric around drug pricing. we'll have to see if earnings can change that story, melissa. >> all right. thank you very much, seema mody. so, dan, how -- >> that rhetoric is really interesting in a lot of ways. i've been kind of saying this over the last couple weeks, that i don't think hillary clinton is elizabeth warren. and i think there is a lot of really bad news priced into the biotech sector. the real fear is the democrats would win the presidency, win the senate and then they win the house. and then, you know, the headwinds about pricing, drug pricing, become a very big deal. i don't think that's all going to happen. so i think that there's a good chance that i

i don't think celgene price gouges their customers. so before next week's earnings, what do you think? >> first of all, thank you for subscribing to action alerts where we address all the stocks my charitable trust owns and then some. second, celgene reports next week and you are absolutely right. i don't think they do any gouging under the new ceo. they've been very straightforward. however, it is an election year, and i have not been pounding the table on any of the pharmaceuticals until after it's over. but i suggest taking no action. it's too low. how about kenneth in florida. kenneth. >> caller: how are you? >> i am good. how about you, kenneth? >> caller: oh, i'm great. i'm so happy to speak to you. you ought to be running for president. >> well, thank you. i'm running for president of cramerica. what's up? >> caller: what's up is hot. >> not great hotel chain, not going to recommend it. if you want to be in the hotel, it's going to be marriott after that merger. i don't like the business in particular because i think a lot of pe

a 3% move in either direction for celgene, bio gen is expected to see a move. this as biotech stocks have fallen 10% over the past month due in part to the political rhetoric around drug pricing. we'll have so see if earnings can change that story. >> all right. thank you very much. so, dan, how do you do that? >> so i've been saying this over the last couple weeks that i don't think hillary clinton is elizabeth warren and i think there's a lot of bad news price into the biotech sector so i think the real fear is that the democrats would win the presidency, they'd win the senate and the house and then you know, the head winds about drug pricing become a very big deal but i don't think that's all going to happen so i think there's a good chance that into year end or maybe into the new year, biotech stocks start to rally. trading in a very well defined range, it's down 20% on the year. it's only up 12% from those lows. that's a problem but i want to look at the xbi. that is the s&p biotech. it's actually made a very nice move off the bottom. a series of high lows

the biotech company, celgene. to do better in the future they say and surprisingly good results from a cancer drug and celgene is up 6 1/2% to be precise, 104 on biotech. that's the company. celgene. wikileaks released more e-mails, means more trouble for the clintons. this time for the clinton foundation. liz, you've got a great story, wh liz: you're looking at doug on the screen next to bill clinton there. he basically arranged for 116 million dollars in personal business to bill clinton. that was as of 2011. so, 116 million in the form of speeches, outside consulting work and arranging for vacation and corporate jet travel for bill clinton. stuart: from the foundation? >> liz: yes it was connected to a the foundation. and an outside review because chelsea clinton was worried. and irs is looking at it and behest of 64 republicans who said this is pay to play and could be nonprofit law violations here. stuart: 116 million dollars, to bill clinton from the foundation. all right. thank you. still on the clinton sca

a name like celgene, for example, has the opportunity to double their earnings over three-to-five yearket multiple or below. hard to find that growth trading discount to the market. election is big overhang. once the election is over we think the stock should do quite well. liz: you're feeling confident how this world is looking for economy and markets? >> i think from a jobs perspective, jobs numbers come in at healthy clip month after month after month. we continue to get more of the same there. that means the market keeps chugging along. liz: chugging along. we're down 12 points for dow joan industrials. s&p lower, same for russell. so much news today. we want to thank lew penditosi of eaton vance. markets set to close ahead of tomorrow's market report and 2:00 a.m. landfall of matthew. david and melissa pick it up for "after the bell". [closing bell yanks. melissa: i'm melissa francis. david: i'm david asman. we have you big market news. hurricane matthew a massive category 4 storm barreling down on florida. this is the strongest storm to hit the u.s. in over a decade. we're hours

celgene, you have up side there, and i went after illumina again because i think that's a good long-term story. these are short-term broken, but i think longer term i like them. i started buying more financials yesterday because i really thought that yesterday was a reaction to china, and today you have seen jp morgan's numbers, and as we go into the quarter, you'll be better off there. >> you buy anything? >> i did. i did. >> i like it much higher than many analysts do for the long-term. >> this week i'm buying fxi and eem. i'm buying the emerging market stocks that have underperformed over the last month, and the reason for that is we saw the china data that came out overnight. ppi is now turning positive. it's the first time in almost five years where ppi is actually positive. that's a tremendous earnings power behind the chinese corporates. >> i think you at the inflexion point. i thi it's in the emerging market stocks. that's what's going to start to do better. particularly as we're looking into next year. >> we're starting to see growth. >> you didn't see anything in the numbers ye

you buy some celgene, and then it suddenly has a patent issue, or you sell du pont the day before a noted activist takes a stake and sends it soaring. next you're filled with self-doubt. that's nonsense. get it together. the market requires you to have the right head on at all times. you have to be ready to see the there's no time to get down on yourself. do that for fantasy if you cut like brady or something. if you want to be introspective and constructive, bracket some time at the end of each month or maybe at the end of a quarter to assess your strategy and your stock-picking abilities. but to second guess your strategy is to put yourself in a loser mind set. i want the pain felt. when i thought one of the younger people in my office made a mistake that was costly to me, i made them wear the symbol of the stock that they screwed up on as a post it on their forehead for the day. i even sent them outside. but i insist that anytime saying if only i is time that takes you from getting the next big stock. karen cramer believed that women are much better traders than men because they lack t

elexion being one and celgene being another, and another one that's up on m&a rumors, but is actuallyn it was when they had a particularly important announcement on a pipeline drug is biogen where. >> you think biogen is a takeover target? >> i think there's a lot of smoke to that, meg. you know, we'll see. there's been some behavioral differences by the company since all this stuff came out. is there something going on? yeah. >> this could be a multi-billion dollar drug. if you look at the stock, it's lower today than it was the day before they announced, you know, the trial and the intent to file early. >> chris raymond. hey, chris, a pleasure to have you on. we appreciate it. >> thanks, guys. >> here's what's coming up on ""the halftime report."" >> samsung slashing its profit outlook after pulling the plug on the note 7. but not everyone is running from the company. plus, amazon is launching a music streaming service and going where no other company has gone before. we've got the details. and beats and misses. the names that could hit it out of the park this earnings season. and t

celgene also up 6% after reporting a positive quarter, people happy with how their franchises are doingen on the opposite side of that, its multisclerosis drug, folks are worried about the pricing. analysts call it solid. vertex down as people fear what's going on with their pipeline of cystic fibrosis drugs. one person suggests it's down because we're not seeing a lot of m&a right now, nothing to keep a floor on these biotech earnings heading into the election, which is the biggest fear on everybody's mind right now. we're halfway through earnings season. the biggest one to watch is going to be next week with gilead. >> and on every single pricing call, i imagine pricing is brought up. >> that's right. a lot of questions about the election, pricing, and prop 61 in california. this issue is really fascinating, the drug industry just hates this proposition. i'll be interested to see how this turns out. >> meg, get back on that blue phone, thank you. so, guy. >> a couple of trades. kite pharmaceuticals, had a huge run, they've given it all back. that gives you an opportunity. a name like

this is about -- >> that is having an impact as you might expect it would on biogen, gilead, celgene great day yesterday, it's down a bit, all the other drug companies, merck is down 2%. >> merck had such a good quarter. it's really -- you know, another one. >> lily down over 2%, so amgen having an impact on the group, not to mention this news from mckesson which has accelerated loss to over quarter of its market value. >> yeah, i got to do more work any time a stock down that much, pretty good company. but i think these guys can't wait for that election. i wonder how valeant's doing. >> i'm sure valeant's kicking butt. oh, yeah. >> taking no prisoners over there? >> yeah. >> look at these declines. these are companies -- you know, for years these were the companies that you just heard people buy, like united health, buy, mckesson, what are you doing in health care, got to stay away from drugs, going to buy cardinal, and then cvs and goes buy care mark so you like cvs more. and next thing you know in one day, in one day they take away mckesson -- that's breathtaking. >> it really is.

celgene stock one way trip down of course we may have to rethink that.eavily involved in the political season. >> they are. after the bell we get earnings from amazon and google. and as you might -- or alphabet, excuse me, as you might anticipate a lot of, well, expectation there. some nervousness on the part of investors when it comes to amazon's earnings, guys, in part because they -- this quarter lapse the first introduction of that prime day which did very well. >> it's very good point. >> and so if you're looking for the same kind of comps on sales this year over last year, you got to remember last year over the year prior last year was the first year, you following, that included prime which helped that prime day really did help. >> scrutable on the conference call, conference calls from amazon sometimes they decide to tell you a lot, sometimes they choose not to. >> now we have this business inside report of plans for physical grocery stores. i know you tweeted that this morning. >> yes, i thought it was very important. >> the notion of having 2,0

at one of the areas of strength and health care, that's because we had earnings in bristol-myers, celgene, and alexi on. as for alexi on, that company's earnings estimates partly because of sales of its drug that treats a rare blood disorder. sales of that drug up 9.6 percent. raising its forecast as well. we're watching oil and oil earnings today. itself is higher. we did have reuters reporting that saudi arabia and its gulf allies are willing to cut 4% from their peak oil output. that is one of the things powering oil higher. then we have earnings from conoco did have reuters reportig that saudi arabia and its gulf phillips, deepening itst spending cuts, and eqt, which is a midstream oil producer. aat company reporting narrower loss that had been estimated to read i also want to mention is tied from what we are seeing in oil, going on with stocks, also what's going on with bonds, we are seeing a global bond rout today. if you look at wb on the bloomberg, that is her world bonds monitor. phillips,i want to point out tn right here. there looking at bonds from americas to europe, the midea

celgene as well in the biotech pharma industry, also beating because of higher cancer drug sales.ighest level since britons vote to leave the e.u. but is the bond rout over done? premarket.s up in we will have more on the carmaker's outlook ahead. ♪ jonathan: from new york, this is bloomberg daybreak. a shakeout in the bond market over the past couple of months. 10 year u.s. treasury yields have popped back up and we have a situation where the yield is above the median year-end forecast by the analysts. they year-end forecast is your white line around 175. where we trade at the moment is the blue line, north of 180. i want to bring in robert leary. typically you come into a new year. typically this is how it goes. equities bullish and bonds bearish. you see that on repeat year after year. that chart shows you a situation where actually the bond market has gone the other way. the bullish bond analysts now look maybe a little bit out of sync. rob: our view is that while we are very happy to see the 10 year at 182, we think it is not going to go up much and that is true even though w